Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Leases: 2019-2024

Historic Current Leases for Seres Therapeutics (MCRB) over the last 6 years, with Dec 2024 value amounting to $8.7 million.

  • Seres Therapeutics' Current Leases rose 18.86% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 18.86%. This contributed to the annual value of $8.7 million for FY2024, which is 55.25% up from last year.
  • Latest data reveals that Seres Therapeutics reported Current Leases of $8.7 million as of FY2024, which was up 55.25% from $5.6 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Current Leases registered a high of $8.7 million during FY2024, and its lowest value of $3.6 million during FY2022.
  • For the 3-year period, Seres Therapeutics' Current Leases averaged around $6.0 million, with its median value being $5.6 million (2023).
  • As far as peak fluctuations go, Seres Therapeutics' Current Leases crashed by 45.52% in 2022, and later soared by 55.25% in 2024.
  • Over the past 5 years, Seres Therapeutics' Current Leases (Yearly) stood at $5.1 million in 2020, then rose by 29.23% to $6.6 million in 2021, then crashed by 45.52% to $3.6 million in 2022, then spiked by 55.15% to $5.6 million in 2023, then skyrocketed by 55.25% to $8.7 million in 2024.